Table IV.
Data from seven studies contributing to summary effect estimates for ovarian cancer risk in non-aspirin NSAID users [7,13,14,19–21]
| Author | Year | Cases | "Regular Use" Definition | RR (95% CI) | |
|---|---|---|---|---|---|
| Case-Control | |||||
| Rosenberg | 2000 | 780 | ≥ 4×/wk | 0.50 (0.30–0.90) | |
| Merritt | 2008 | 1,576 | ≥ 2×/wk | 0.83 (0.66–1.04) | |
| Wu a | 2009 | 609 | ≥ 1×/wk | 1.68 (1.23–2.23) | |
| Cohort Studies | |||||
| Lacey | 2004 | 116 | ≥ 1×/wk | 1.00 (0.60–1.80) | |
| Pinheiro | 2009 | 666 | ≥ 2×/wk | 0.81 (0.64–1.01) | |
| Prizment | 2010 | 167 | ≥ 1×/wk | 0.89 (0.64–1.23) | |
| AARP | 2012 | 438 | ≥ 1×/wk | 0.93 (0.74–1.15) | |
a.
Estimate associated with "regular use" definition was determined by pooling two or more estimates provided in the manuscript.